Characteristics and outcome of ischemic stroke patients who are free of symptoms at 24 hours following thrombolysis

Cerebrovascular Diseases

Volumn 31, Issue 1, 2010, Pages 37-42

  Strbian, Daniel ^a   Sairanen, Tiina ^a   Rantanen, Kirsi ^a   Piironen, Katja ^a   Atula, Sari ^a   Tatlisumak, Turgut ^a   Soinne, Lauri ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Ischemic stroke; Outcome; Thrombolysis

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; GLUCOSE; STATIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE; BRAIN INFARCTION; BRAIN ISCHEMIA; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME;

AGE FACTORS; AGED; BLOOD GLUCOSE; BRAIN ISCHEMIA; DISABILITY EVALUATION; FEMALE; FIBRINOLYTIC AGENTS; FINLAND; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT ADMISSION; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77958457978     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320263     Document Type: Article

References (10)

1. Hacke W, Donnan G, Fieschi C, et al: Association of outcome with early stroke treatment: pooled analysis of Atlantis, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.
2. Albers GW, Bates VE, Clark WM, et al: Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-1150.
3. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study Investigators: Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172:1307-1312.
4. Wahlgren N, Ahmed N, Davalos A, et al: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-282.
5. NINDS Study Investigators: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
6. Uchino K, Massaro L, Hammer MD: Transient ischemic attack after tissue plasminogen activator: aborted stroke or unnecessary stroke therapy? Cerebrovasc Dis 2010;29:57-61.
7. Saposnik G, di Legge S, Webster F, et al: Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology 2005;65:1169-1174.
8. Brown DL, Johnston KC, Wagner DP, et al: Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke. Stroke 2004;35:147-150.
9. Adams HP Jr, Bendixen BH, Kappelle LJ, et al: Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
10. Kharitonova T, Ahmed N, Thorén M, et al., for the SITS Investigators: Hyperdense middle cerebral artery sign on admission CT scan: prognostic significance for ischaemic stroke patients treated with intravenous thrombolysis in the Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Register. Cerebrovasc Dis 2009;27:51-59.